𩺠å
§ç§å°ç§èåç
ð äžé éé»
- 22E: SGLT2i + bisphosphonate + denosumab roles
- 1° HPT diagnostic criteria æŽæ°
- Taiwan: lithium-induced hyperCa, MEN-1/2 monitoring
ð é²é
Primary HPT Surgery Indications
- Symptoms (stone, bone, etc.)
- Asymptomatic with:
- Age < 50
- Ca > 1 mg/dL above ULN
- Bone density T-score †-2.5
- Vertebral fracture
- Renal stone / nephrocalcinosis
- GFR < 60
- Urine Ca > 400
Cinacalcet (Calcimimetic)
- Activates CaSR â â PTH
- For 2°/3° HPT (CKD), parathyroid carcinoma, refractory 1° HPT
- Side: GI, hypoCa
Etelcalcetide
- IV calcimimetic for HD patients
MEN Syndromes
- MEN-1: Pituitary, Parathyroid, Pancreas
- MEN-2A: Medullary thyroid, Pheochromocytoma, Parathyroid
- MEN-2B: Medullary thyroid, Pheo, Mucosal neuroma
Pseudohypoparathyroidism (PHP)
- Type 1A (Albright): GNAS mutation, Albright osteodystrophy
- End-organ PTH resistance
- High PTH but low Ca
Hungry Bone Syndrome
- Post-parathyroidectomy in severe HPT
- Severe hypoCa, hypoP, hypoMg
- Aggressive replacement
ð Pearls (10)
- Always measure ionized Ca in critical care (not total)
- PTH-suppressed hyperCa â workup malignancy + granulomatous + vit D
- FHH distinguishes from 1° HPT by urine Ca/Cr clearance ratio
- Lithium: shifts CaSR setpoint
- Cinacalcet for parathyroid carcinoma + 3° HPT
- Bisphosphonate ONJ prevention with dental clearance
- Denosumab discontinuation rebound osteoclast activity
- Hungry bone syndrome = aggressive replacement
- Pseudohypoparathyroidism = end-organ resistance
- Vit D toxicity from supplements rising
ð Taiwan Context
- å¥ä¿ bisphosphonate / denosumab
- Cinacalcet for HD with 2°/3° HPT
- Parathyroidectomy æ®å
ð å
§å°éé»
- PTH-dependent vs suppressed
- 1° HPT surgery indications
- Bisphosphonate / denosumab / cinacalcet
- MEN syndromes
- Pseudohypoparathyroidism
- Hungry bone
â ïž AI èçš¿ã